Survodutide

Vialdyne buyer fit

Overview

Survodutide, carrying the development code BI 456906, is an investigational dual co-agonist hitting the GLP-1 and glucagon receptors. The clinical-development program runs through a Boehringer Ingelheim / Zealand Pharma partnership and is in Phase 3 for both chronic weight management and metabolic-liver indications, MASH (metabolic-associated steatohepatitis) chief among them. Receptor coverage maps to GLP-1R plus GCGR with no GIP arm, mirroring Mazdutide and contrasting with the GIP-containing dual / tri-agonist class. That positioning makes the molecule useful in two distinct ways: as a research tool for studying glucagon-pathway pharmacology isolated from GIP signalling, and as a clinical asset for indications where glucagon-mediated hepatic energy expenditure delivers therapeutic value. For research-lab buyers, Vialdyne releases Survodutide acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The catalogue 10 mg fill covers bench-scale aliquot work in the typical research context. The release packet leans particularly hard on ESI-MS identity confirmation, the structural proximity to other GLP-1 / glucagon dual co-agonists means catalogue-level cross-supplier confusion is an operationally real failure mode, and LC-MS/MS sequence verification can be included when required by the buyer’s written analytical scope.

Applications & buyer fit

Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

2805997-46-8

Appearance

White lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 6 days

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for Survodutide; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Survodutide

VD260428-MX192 · 99.24%

Regulatory note

An investigational compound advancing through Phase 3 development at Boehringer Ingelheim / Zealand Pharma, this has not been approved as a finished drug. Supply is for research use only. Although a CAS is commonly cited, verify it per batch COA.

Selected literature

1. le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173.
2. Sanyal AJ, Bedossa P, Fraessdorf M, et al; 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319.
3. le Roux CW, Wharton S, Startseva E, et al; SYNCHRONIZE-1 Investigators. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026 Jun 7. [Epub ahead of print].
4. Sanyal AJ, Newsome PN, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026 Jun 8. [Epub ahead of print].
5. Wharton S, le Roux CW, Kosiborod MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity (Silver Spring). 2025;33(1):67-77.

Frequently asked questions